MedTrace Logo

Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt

NCT02247401 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2021-07-30

Study results available
· View outcomes & findings →

Summary

This study evaluates the efficacy and safety of ABT-450/r/ABT-267 with RBV in treatment-naive and treatment-experienced HCV GT4 subjects without or with compensated cirrhosis.

Conditions

  • HCV
  • Hepatitis C Infection
  • Genotype 4

Interventions

DRUG

2 DAA

ABT-450/r/ABT-267 tablets

DRUG

RBV

Ribavirin tablets

Sponsors & Collaborators

Principal Investigators

  • Sarah Kopecky-Bromberg, PhD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-04
Primary Completion
2016-08-01
Completion
2016-08-01

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02247401 on ClinicalTrials.gov